166 related articles for article (PubMed ID: 18667166)
1. Improvement in soluble expression levels of a diabody by exchanging expression vectors.
Liu F; Chen Z; Jiang W; Yang C; Xiong D; Zhu Z
Protein Expr Purif; 2008 Nov; 62(1):15-20. PubMed ID: 18667166
[TBL] [Abstract][Full Text] [Related]
2. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics.
Kipriyanov SM; Moldenhauer G; Schuhmacher J; Cochlovius B; Von der Lieth CW; Matys ER; Little M
J Mol Biol; 1999 Oct; 293(1):41-56. PubMed ID: 10512714
[TBL] [Abstract][Full Text] [Related]
3. Efficient inhibition of human B-cell lymphoma in SCID mice by synergistic antitumor effect of human 4-1BB ligand/anti-CD20 fusion proteins and anti-CD3/anti-CD20 diabodies.
Liu R; Jiang W; Yang M; Guo H; Zhang Y; Wang J; Zhu H; Shi R; Fan D; Yang C; Zhu Z; Xie Y; Xiong D
J Immunother; 2010 Jun; 33(5):500-9. PubMed ID: 20463597
[TBL] [Abstract][Full Text] [Related]
4. Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent.
Asano R; Sone Y; Makabe K; Tsumoto K; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
Clin Cancer Res; 2006 Jul; 12(13):4036-42. PubMed ID: 16818703
[TBL] [Abstract][Full Text] [Related]
5. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.
Bühler P; Wolf P; Gierschner D; Schaber I; Katzenwadel A; Schultze-Seemann W; Wetterauer U; Tacke M; Swamy M; Schamel WW; Elsässer-Beile U
Cancer Immunol Immunother; 2008 Jan; 57(1):43-52. PubMed ID: 17579857
[TBL] [Abstract][Full Text] [Related]
6. Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells.
Asano R; Kawaguchi H; Watanabe Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
J Immunother; 2008 Oct; 31(8):752-61. PubMed ID: 18779744
[TBL] [Abstract][Full Text] [Related]
7. Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 x anti-CD3 bispecific diabody.
Xiong D; Xu Y; Liu H; Peng H; Shao X; Lai Z; Fan D; Yang M; Han J; Xie Y; Yang C; Zhu Z
Cancer Lett; 2002 Mar; 177(1):29-39. PubMed ID: 11809528
[TBL] [Abstract][Full Text] [Related]
8. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.
Gall JM; Davol PA; Grabert RC; Deaver M; Lum LG
Exp Hematol; 2005 Apr; 33(4):452-9. PubMed ID: 15781336
[TBL] [Abstract][Full Text] [Related]
9. [One amino acid mutation in an anti-CD20 antibody fragment that affects the yield bacterial secretion and the affinity].
Liu YX; Xiong DS; Fan DM; Shao XF; Xu YF; Zhu ZP; Yang CZ
Sheng Wu Gong Cheng Xue Bao; 2003 May; 19(3):272-6. PubMed ID: 15969005
[TBL] [Abstract][Full Text] [Related]
10. CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis.
Mølhøj M; Crommer S; Brischwein K; Rau D; Sriskandarajah M; Hoffmann P; Kufer P; Hofmeister R; Baeuerle PA
Mol Immunol; 2007 Mar; 44(8):1935-43. PubMed ID: 17083975
[TBL] [Abstract][Full Text] [Related]
11. Efficient inhibition of multidrug-resistant human tumors with a recombinant bispecific anti-P-glycoprotein x anti-CD3 diabody.
Gao Y; Xiong D; Yang M; Liu H; Peng H; Shao X; Xu Y; Xu C; Fan D; Qin L; Yang C; Zhu Z
Leukemia; 2004 Mar; 18(3):513-20. PubMed ID: 14981526
[TBL] [Abstract][Full Text] [Related]
12. Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation.
Cochlovius B; Kipriyanov SM; Stassar MJ; Schuhmacher J; Benner A; Moldenhauer G; Little M
Cancer Res; 2000 Aug; 60(16):4336-41. PubMed ID: 10969772
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activities of PSMA×CD3 diabodies by redirected T-cell lysis of prostate cancer cells.
Baum V; Bühler P; Gierschner D; Herchenbach D; Fiala GJ; Schamel WW; Wolf P; Elsässer-Beile U
Immunotherapy; 2013 Jan; 5(1):27-38. PubMed ID: 23256796
[TBL] [Abstract][Full Text] [Related]
14. Target-dependent T-cell activation by coligation with a PSMA x CD3 diabody induces lysis of prostate cancer cells.
Bühler P; Molnar E; Dopfer EP; Wolf P; Gierschner D; Wetterauer U; Schamel WW; Elsässer-Beile U
J Immunother; 2009; 32(6):565-73. PubMed ID: 19483653
[TBL] [Abstract][Full Text] [Related]
15. A new format of bispecific antibody: highly efficient heterodimerization, expression and tumor cell lysis.
Xie Z; Guo N; Yu M; Hu M; Shen B
J Immunol Methods; 2005 Jan; 296(1-2):95-101. PubMed ID: 15680154
[TBL] [Abstract][Full Text] [Related]
16. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair.
Strop P; Ho WH; Boustany LM; Abdiche YN; Lindquist KC; Farias SE; Rickert M; Appah CT; Pascua E; Radcliffe T; Sutton J; Chaparro-Riggers J; Chen W; Casas MG; Chin SM; Wong OK; Liu SH; Vergara G; Shelton D; Rajpal A; Pons J
J Mol Biol; 2012 Jul; 420(3):204-19. PubMed ID: 22543237
[TBL] [Abstract][Full Text] [Related]
17. Construction of a diabody (small recombinant bispecific antibody) using a refolding system.
Takemura S; Asano R; Tsumoto K; Ebara S; Sakurai N; Katayose Y; Kodama H; Yoshida H; Suzuki M; Imai K; Matsuno S; Kudo T; Kumagai I
Protein Eng; 2000 Aug; 13(8):583-8. PubMed ID: 10964988
[TBL] [Abstract][Full Text] [Related]
18. Treatment of human B cell lymphoma xenografts with a CD3 x CD19 diabody and T cells.
Cochlovius B; Kipriyanov SM; Stassar MJ; Christ O; Schuhmacher J; Strauss G; Moldenhauer G; Little M
J Immunol; 2000 Jul; 165(2):888-95. PubMed ID: 10878363
[TBL] [Abstract][Full Text] [Related]
19. [Construction and expression of human 4-1BBL/anti-CD20 fusion protein].
Liu R; Jiang WG; Liu F; Zhang YJ; Fan DM; Yang M; Xiong DS; Yang CZ
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Jun; 24(6):543-5. PubMed ID: 18538078
[TBL] [Abstract][Full Text] [Related]
20. [Study on the construction and expression of the human 4-1BBL extracellular domain/anti-CD20 Fab' fusion protein].
Jiang W; Xiong D; Liu F; Guo H; Su Y; Lü J; Yang C
Sheng Wu Gong Cheng Xue Bao; 2008 Mar; 24(3):376-80. PubMed ID: 18589811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
